专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2009134086A9 PHARMACEUTICAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASE 审中-公开
标题翻译：药物制剂治疗心血管疾病
公开(公告)号：WO2009134086A9
公开(公告)日：2010-03-11
申请号：PCT/KR2009002278
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Valsartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (5) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and an Iresartan-containing retarded release compartment, and (7) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Candesartan-containing retarded release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with a single medication or a simply combined medication.
摘要翻译：本发明提供了（1）释放控制的药物制剂，其包含含有辛伐他汀的早期释放隔室和含有氯沙坦的缓释隔室，（2）释放控制的药物制剂，其包含含有辛伐他汀的早期释放隔室和奥美沙坦（3）包含含有辛伐他汀的早期释放隔室和含有缬沙坦的缓释隔室的释放控制药物制剂，（4）包含含有辛伐他汀的早期释放隔室的释放控制药物制剂和（5）包含含有罗苏伐他汀的早期释放隔室和含有氯沙坦的缓释隔室的释放控制药物制剂，（6）包含含有瑞舒伐他汀的早期释放的释放控制药物制剂隔间（7）含有含瑞舒伐他汀的早释隔室和含坎地沙坦的缓释隔室的释放控制药物制剂。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化，并使药物的独特作用最大化，因为制剂中不同药物所含的不同药物以时间差异释放。通过两种药物的特定组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出显着优异的疾病治疗或预防效果。

32. 发明申请

WO2009134076A3 COMBINED COMPOSITION FOR CONTROLLED-RELEASE OF ANGIOTENSIN-II-RECEPTOR BLOCKER AND HMG-COA REDUCTASE INHIBITOR 审中-公开
标题翻译：用于控制释放血管紧张素II受体阻断剂和HMG-COA还原酶抑制剂的组合物
公开(公告)号：WO2009134076A3
公开(公告)日：2010-02-18
申请号：PCT/KR2009002256
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/26 , A61K47/00
CPC分类号： A61K45/06
摘要： The present invention relates to a controlled-release combination of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, in which each ingredient of the combination can be control-released at a specific rate based on the different in-vivo expressions of each ingredient. The present invention is a combined pharmaceutical composition which is effective for treatment of hypertension and prevention of complications in the medical complication known as the metabolic syndrome wherein diabetes, obesity, hyperlipidemia, coronary artery disease and the like, appear in combination, and to a preparation method thereof. More particularly, the present invention relates to a controlled-release drug delivery system for a combination of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor which releases the drugs at optimal rates for their in vivo absorption, maximizes effects and improves patient compliance.
摘要翻译：本发明涉及血管紧张素-II受体阻断剂和HMG-CoA还原酶抑制剂的控释组合，其中组合的每种成分可以基于不同的体内表达以特定的速率进行控制释放的每种成分。本发明是一种组合药物组合物，其有效治疗高血压，预防与已知的糖尿病，肥胖症，高脂血症，冠状动脉疾病等组合出现的代谢综合征的医疗并发症的并发症，以及制剂方法。更具体地，本发明涉及用于血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的组合的控释药物递送系统，其以最佳速率释放药物用于其体内吸收，使效果最大化并且改善患者依从性。

33. 发明申请

WO2009134056A3 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134056A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002224
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/26 , A61K47/00
CPC分类号： A61K9/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing hydrochlorothiazide as a pharmacologically active ingredient and an extended-release compartment containing losartan as a pharmacologically active ingredient. Since the formulation of the present invention can deliver hydrochlorothiazide and losartan at a specific rate at different times, it is very effective in treating hypertension and preventing complications, and has the effects of improving the adaptation rate of the patient, optimizing drug delivery time and reducing side effects.
摘要翻译：本发明提供了包含含有氢氯噻嗪作为药理活性成分的立即释放室和含有氯沙坦作为药理活性成分的延长释放室的药物制剂。由于本发明的制剂可以在不同时间以特定的速率递送氢氯噻嗪和氯沙坦，因此在治疗高血压和预防并发症方面非常有效，并且具有改善患者适应率，优化药物递送时间和减少副作用。

34. 发明申请

WO2009134079A9 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134079A9
公开(公告)日：2010-03-11
申请号：PCT/KR2009002261
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO , LEE YOUNG JOO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44 , A61K47/00
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Irbesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Valsartan-containing retard release compartment, (5) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Telmisartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (7) a release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and a Losartan-containing retarded release compartment, and (8) release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and an Irbesartan-containing retard release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含阿托伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含阿托伐他汀的早期释放隔室和厄贝沙坦的释放控制药物制剂（3）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含有奥美沙坦的缓释隔室，（4）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含缬沙坦的延迟释放隔室，（5）包含含阿托伐他汀的早期释放隔室和含替米沙坦的缓释隔室的释放控制药物制剂，（6）包含含阿托伐他汀的早期释放的释放控制药物制剂 COM （7）包含匹伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，和（8）包含匹伐他汀的释放控制药物制剂早泄室和含有厄贝沙坦的缓释隔室。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的具体组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出非常优异的治疗或预防疾病的效果。

35. 发明申请

WO2009134053A3 PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDE-BASED COMPOUND WITH CONTROLLED RELEASE AND ANGIOTENSIN-II-RECEPTOR BLOCKER 审中-公开
标题翻译：含有受控释放的二氧化硫化合物和血管紧张素II受体阻断剂的药物组合物
公开(公告)号：WO2009134053A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002219
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON
IPC分类号： A61K9/22 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/616
CPC分类号： A61K9/00
摘要： The present invention relates to a pharmaceutical composition in which release of a thiazide-based compound and angiotensin-II-receptor blocker is controlled, and to a combination preparation technique for the same. More particularly, the present invention relates to a preparation technique capable of maximizing pharmacological and clinical blood pressure control effects and complication preventive effects and significantly reducing side effects by administrating a release-controlled combination preparation rather than administrating a single preparation of thiazide-based compound and a single preparation of angiotensin-II-receptor blocker at the same time.
摘要翻译：本发明涉及一种其中控制了噻嗪类化合物和血管紧张素-II受体阻断剂释放的药物组合物及其组合制备技术。更具体地，本发明涉及一种能够通过施用释放控制的组合制剂而不是施用单一制剂的噻嗪类化合物而使药理学和临床血压控制效果和并发症预防效果最大化并显着降低副作用的制备技术，同时单次制备血管紧张素-II受体阻滞剂。

36. 发明申请

WO2009125987A3 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A3
公开(公告)日：2009-12-03
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶类钙通道阻滞剂的延长释放室和具有血管紧张素-2受体阻断剂的立即释放室的药物制剂。本发明提供了药物制剂，其中二氢吡啶类钙通道阻滞剂和血管紧张素-2受体阻断剂分别包含在每个隔室中，并且其释放被控制。由于制剂的每个不同隔室中包含的每种不同药物在不同的时间被释放，所以本发明的药物制剂使药物之间的拮抗作用和副作用最小化并使药物的具体效果最大化。根据本发明的两种药物之间的具体组合，通过与各药物的单次给药或药物的简单组合给药，治疗或预防疾病具有显着的效果。

37. 发明申请

WO2009125944A3 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER 审中-公开
标题翻译：含有非二氢吡啶钙通道阻断剂和血管紧张素-2受体阻滞剂的药物制剂
公开(公告)号：WO2009125944A3
公开(公告)日：2009-12-03
申请号：PCT/KR2009001723
申请日：2009-04-03
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
IPC分类号： A61K9/22 , A61K31/435
CPC分类号： A61K31/435 , A61K9/0004 , A61K9/1676 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/2866 , A61K9/4808 , A61K9/5078 , A61K9/5084 , A61K31/4178 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient and an extended-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. Since the disclosed formulation enables the release of the two ingredients at a different time, it reduces side effects and increases the effects of the drug more than the case of separately administering the ingredients each at the same time. In addition, the formulation maximizes the effects of drug at the time of day when the complication risk of cardiovascular system diseases is highest.
摘要翻译：本发明提供一种药物制剂，其包含含有作为药理活性成分的血管紧张素-2受体阻断剂（ARB）的速释隔室和含有非二氢吡啶钙通道阻断剂作为药理活性成分的缓释隔室。由于所公开的制剂能够在不同的时间释放两种成分，因此与分别同时分别给药成分的情况相比，它减少了副作用并增加了药物的作用。另外，当心血管系统疾病的并发症风险最高时，该制剂在一天中的时间最大化药物的作用。

38. 发明申请

WO2009125944A2 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER 审中-公开
标题翻译：含有非二氢脯氨酸钙通道阻断剂和血管紧张素-2受体阻断剂的药物制剂
公开(公告)号：WO2009125944A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001723
申请日：2009-04-03
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
IPC分类号： A61K9/22 , A61K31/435
CPC分类号： A61K31/435 , A61K9/0004 , A61K9/1676 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/2866 , A61K9/4808 , A61K9/5078 , A61K9/5084 , A61K31/4178 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient and an extended-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. Since the disclosed formulation enables the release of the two ingredients at a different time, it reduces side effects and increases the effects of the drug more than the case of separately administering the ingredients each at the same time. In addition, the formulation maximizes the effects of drug at the time of day when the complication risk of cardiovascular system diseases is highest.
摘要翻译：本发明提供了包含含有作为药理活性成分的血管紧张素-2受体阻断剂（ARB）的立即释放室和含有非二氢吡啶类钙通道阻滞剂作为药理活性成分的延长释放室的药物制剂。由于所公开的配方使得能够在不同时间释放两种成分，所以与同时分别施用各成分的情况相比，其降低副作用并增加药物的效果。此外，当心血管系统疾病的并发症风险最高时，该制剂使药物的效果最大化。

39. 发明申请

WO2009134086A3 PHARMACEUTICAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009134086A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002278
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Valsartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (5) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and an Iresartan-containing retarded release compartment, and (7) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Candesartan-containing retarded release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含有辛伐他汀的早期释放室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含有辛伐他汀的早期释放隔室和奥美沙坦的释放控制药物制剂（3）包含含有辛伐他汀的早期释放隔室和含缬沙坦的缓释隔室的释放控制药物制剂，（4）包含含有辛伐他汀的早期释放隔室的释放控制药物制剂，以及含有Candesartan的延迟释放隔室，（5）包含含有罗苏伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（6）包含含有罗苏伐他汀的早期释放的释放控制药物制剂隔间 d是含有Iresartan的缓释隔室，和（7）包含含有罗苏伐他汀的早期释放隔室和含有Candesartan的延迟释放隔室的释放控制药物制剂。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的特定组合制备的本发明的药物制剂与单一药物或简单组合药物相比显示出非常优异的治疗或预防疾病的效果。

40. 发明申请

WO2009142421A2 PHARMACEUTICAL PREPARATION (PHARMACEUTICAL FORMULATION) 审中-公开
标题翻译：药物制剂（药物制剂）
公开(公告)号：WO2009142421A2
公开(公告)日：2009-11-26
申请号：PCT/KR2009002617
申请日：2009-05-18
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , PARK YUN SANG
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , PARK YUN SANG
IPC分类号： A61K9/22
CPC分类号： A61K9/284 , A61K9/5042
摘要： The present invention provides a pharmaceutical preparation which comprises: an early release zone containing an HMG-CoA reductase inhibitor as a pharmacological active component; and a delayed release zone containing a fibric acid derivative as a pharmacological active component. The pharmaceutical preparation of the present invention is designed in such a way as to allow the controlled release of drugs over a specific time period and at a specific rate, and is highly efficacious in the treatment of hyperlipidaemia.
摘要翻译：本发明提供一种药物制剂，其包含：含有HMG-CoA还原酶抑制剂作为药理活性成分的早期释放区; 以及含有纤维酸衍生物作为药理活性成分的延迟释放区。本发明的药物制剂设计成允许在特定时间段内以特定速率控制药物释放，并且在治疗高脂血症方面是非常有效的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式